智通财经APP讯，中国同辐(01763)发布公告，根据对本集团截至2025年12月31日止年度的未经审核综合管理账目及现时可得数据之初步审阅，预期与2024年同期相比：收益预计约人民币69.79亿元至人民币72.06亿元，同比减少约5%至8%;净利润预计约人民币6.11亿元至人民币6.55亿元，同比减少约25%至30%;本公司权益股东应占年内利润预计约人民币3.02亿元至人民币3.22亿元，同比减少约20%至25%。截至目前，公司经营运作正常，2025年度收益减少主要由于本集团的核医疗装备分部收益下降，利润减少主要由于本公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.